Essex Bio-Technology Ltd
HKEX:1061
Intrinsic Value
Essex Bio-Technology Ltd. is an investment holding company, which engages in the development, manufacture and sale of biopharmaceutical products. [ Read More ]
The intrinsic value of one
Essex Bio-Technology Ltd
stock under the Base Case scenario is
6.01
HKD.
Compared to the current market price of 2.25 HKD,
Essex Bio-Technology Ltd
is
Undervalued by 63%.
Essex Bio-Technology Ltd could be a value trap.A value trap occurs when a stock looks inexpensive based on fundamental analysis but fails to reach its intrinsic valuation over time, often due to underlying issues not reflected in quantitative data.
Scrutinize beyond numbers; assess long-term potential.
Essex Bio-Technology Ltd's market capitalization is 1.3B HKD.
Essex Bio-Technology Ltd stock price is 2.25 HKD.
Essex Bio-Technology Ltd stock price (2.25 HKD) is 63% less than its Intrinsic Value (6.01 HKD).
Essex Bio-Technology Ltd stock price (2.25 HKD) is 65% less than its DCF Value (6.39 HKD). Open DCF Valuation
Essex Bio-Technology Ltd stock price (2.25 HKD) is 60% less than its Relative Value (5.63 HKD). Open Relative Valuation
Essex Bio-Technology Ltd has upside potential of 353% compared to the average analyst price target.
Open Wall St Estimates
Essex Bio-Technology Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 12% to 12%.
Essex Bio-Technology Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 12%.
Essex Bio-Technology Ltd's ROE (Return on Equity) has decreased in the last 3 years from 17% to 15%.
Essex Bio-Technology Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 15%.
Essex Bio-Technology Ltd has positive three-year average ROIC (Return on Invested Capital): 14%. The company is efficient at using invested capital to generate operating income.
Essex Bio-Technology Ltd's Revenue has grown by an exceptional 30% over the past 12 months.
Essex Bio-Technology Ltd has positive Net Income for the last twelve months.
Essex Bio-Technology Ltd has positive Free Cash Flow for the last twelve months.
Essex Bio-Technology Ltd's short-term assets (1B HKD) exceed its short-term liabilties (811m HKD).
Essex Bio-Technology Ltd has positive Operating Income for the last twelve months.
Essex Bio-Technology Ltd has positive three-year average ROE (Return on Equity): 18%. The company is efficient at transforming stockholders' equity into net income.
Essex Bio-Technology Ltd's Altman Z-Score is equal to 2.86.
Essex Bio-Technology Ltd's Revenue has been growing by an exceptional 20% per year for the last 3 years.
Essex Bio-Technology Ltd has positive Gross Profit for the last twelve months.
Essex Bio-Technology Ltd's long-term assets (3B HKD) exceed its long-term liabilties (904m HKD).
Essex Bio-Technology Ltd's D/E (Debt to Equity) is very low and is equal to 0.03.
Essex Bio-Technology Ltd has negative Net Debt. This means that the company has more cash and short-term investments (515m HKD) than debt (56m HKD).
Essex Bio-Technology Ltd earns more than enough operating income (339m HKD) to safely cover interest payments on its debt (16m HKD).
Valuation Backtest
Essex Bio-Technology Ltd
Run backtest to discover the historical profit from buying and selling
Essex Bio-Technology Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Essex Bio-Technology Ltd
Balance Sheet Decomposition
Essex Bio-Technology Ltd
| Current Assets | 1.2B |
| Cash & Short-Term Investments | 515m |
| Receivables | 637.2m |
| Other Current Assets | 93m |
| Non-Current Assets | 1.6B |
| Long-Term Investments | 40.4m |
| PP&E | 405.9m |
| Intangibles | 1.1B |
| Other Non-Current Assets | 25.2m |
| Current Liabilities | 810.7m |
| Accounts Payable | 10.6m |
| Other Current Liabilities | 800.2m |
| Non-Current Liabilities | 93m |
| Long-Term Debt | 56.5m |
| Other Non-Current Liabilities | 36.6m |
Earnings Waterfall
Essex Bio-Technology Ltd
|
Revenue
|
1.7B
HKD
|
|
Cost of Revenue
|
-167.3m
HKD
|
|
Gross Profit
|
1.5B
HKD
|
|
Operating Expenses
|
-1.2B
HKD
|
|
Operating Income
|
338.9m
HKD
|
|
Other Expenses
|
-63.6m
HKD
|
|
Net Income
|
275.3m
HKD
|
Free Cash Flow Analysis
Essex Bio-Technology Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Essex Bio-Technology Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Essex Bio-Technology Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Essex Bio-Technology Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Score
Essex Bio-Technology Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Essex Bio-Technology Ltd
According to Wall Street analysts, the average 1-year price target for
Essex Bio-Technology Ltd
is 10.2 HKD
.
Shareholder Return
Price
Essex Bio-Technology Ltd
| Average Annual Return | -9.27% |
| Standard Deviation of Annual Returns | 23.35% |
| Max Drawdown | -75% |
| Market Capitalization | 1.3B HKD |
| Shares Outstanding | 567 539 968 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Essex Bio-Technology Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Essex Bio-Technology Ltd. is an investment holding company, which engages in the development, manufacture and sale of biopharmaceutical products. The company employs 1,379 full-time employees The company went IPO on 2001-06-27. The firm develops biopharmaceutical drugs based on recombinant deoxyribonucleic acid (DNA) technology. The main brands of the Company's products are Beifuji, Beifushu and Beifuxin. The firm operates through two business segments. The Pharmaceutical Products segment is engaged in the development, manufacture and sales of pharmaceutical products. The Provision of Marketing Services segment is involved in the distribution of third party products and provision of marketing services to such third party’s products.
Contact
IPO
Employees
Officers
The intrinsic value of one
Essex Bio-Technology Ltd
stock under the Base Case scenario is
6.01
HKD.
Compared to the current market price of 2.25 HKD,
Essex Bio-Technology Ltd
is
Undervalued by 63%.
You don't have any saved screeners yet
